Property:Outcome name
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
* [[Allows value::Anxiety]] | * [[Allows value::Anxiety]] | ||
* [[Allows value::Appetite]] | * [[Allows value::Appetite]] | ||
* [[Allows value::BMD (Bone Mineral Density)]] | |||
* [[Allows value::Body composition]] | * [[Allows value::Body composition]] | ||
* [[Allows value::Carnitine level]] | * [[Allows value::Carnitine level]] | ||
* [[Allows value::Carotenoid concentration]] | * [[Allows value::Carotenoid concentration]] | ||
| Line 51: | Line 51: | ||
* [[Allows value::Nausea]] | * [[Allows value::Nausea]] | ||
* [[Allows value::Nausea and Vomiting]] | * [[Allows value::Nausea and Vomiting]] | ||
* [[Allows value::Neutropenia]] | * [[Allows value::Neutropenia]] | ||
* [[Allows value::Non-haematological indices]] | * [[Allows value::Non-haematological indices]] | ||
| Line 59: | Line 58: | ||
* [[Allows value::Ototoxicity]] | * [[Allows value::Ototoxicity]] | ||
* [[Allows value::Pain]] | * [[Allows value::Pain]] | ||
* [[Allows value::PD (Pharmacodynamics)]] | |||
* [[Allows value::Performance Status]] | * [[Allows value::Performance Status]] | ||
* [[Allows value::Peripheral neuropathy]] | |||
* [[Allows value::PFS (Progression-Free Survival)]] | * [[Allows value::PFS (Progression-Free Survival)]] | ||
* [[Allows value::Pharyngitis]] | * [[Allows value::Pharyngitis]] | ||
* [[Allows value::PK (Pharmacokinetics)]] | |||
* [[Allows value::PSADT (Prostate-Specific Antigen Doubling Time)]] | * [[Allows value::PSADT (Prostate-Specific Antigen Doubling Time)]] | ||
* [[Allows value::PSA level (Prostate-Specific Antigen)]] | * [[Allows value::PSA level (Prostate-Specific Antigen)]] | ||
Revision as of 07:05, 15 July 2024
This is a property of type Text.
The allowed values for this property are:
- Anorexia/Cachexia
- Antibodies
- Anxiety
- Appetite
- BMD (Bone Mineral Density)
- Body composition
- Carnitine level
- Carotenoid concentration
- Cerebral oedema
- CINV (Chemotherapy-Induced Nausea and Vomiting)
- Cognitive functioning
- Cognitive impairment
- Depression
- Dermatitis
- DFS (Disease-Free Survival)
- Diarrhoe
- Distress
- Duration of fever
- Dysgeusia
- EFS (Event-Free Survival)
- Ejection fraction
- Emesis
- Erectile dysfunction
- Esophagitis
- Fatigue
- Fibrosis
- Folic acid level
- Functionality
- Haematological indices
- Haematological toxicity
- Hand-foot syndrome
- Hand grip strength
- Hepatotoxicity
- Hot flushes
- Hormone level
- Incidence of acute GVHD (Graft-Versus-Host Disease)
- Ileus (intestinal obstruction)
- Length of hospital stay
- LFS (Local-Free Survival)
- Lymphedema
- Menopausal symptoms
- MFS (Metastases-Free Survival)
- Mood/Affect
- Mortality rate
- MTD (Maximum Tolerated Dose)
- Mucositis
- Musculoskeletal symptoms
- Nausea
- Nausea and Vomiting
- Neutropenia
- Non-haematological indices
- Nutrition status
- Objective signs and subjective symptoms
- OS (Overall Survival)
- Ototoxicity
- Pain
- PD (Pharmacodynamics)
- Performance Status
- Peripheral neuropathy
- PFS (Progression-Free Survival)
- Pharyngitis
- PK (Pharmacokinetics)
- PSADT (Prostate-Specific Antigen Doubling Time)
- PSA level (Prostate-Specific Antigen)
- Quality of life
- Recurrence rate
- Reduction of complication rates
- Relaxation
- Restoration of bowel function after surgery
- RFS (Recurrence-Free Survival)
- Salivary gland function
- Seroconversion
- Selenium level
- Shoulder mobility
- Side effects of androgen deprivation/suppression
- Skeletal morbidity-free survival
- Sleep
- Stress
- Taste alteration
- Tea polyphenol uptake
- Thromboembolic event rates
- Toxicity
- Tumor progression
- Tumor response
- Vaginal atrophy
- Vitamin A level
- Vitamin B6 level
- Vitamin B12 level
- Vitamin B17 level
- Vitamin C level
- Vitamin D level
- Vitamin E level
- Vomiting
- Weight
- Well-being
- Wound healing
- Wound odour
- Xerostomia
- Zinc level
- Unspecified effects
- NI
- ?
A
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
Toxicity +
Afonseca et al. (2013): Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: A pilot randomized clinical trial +
Peripheral neuropathy +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
RFS (Recurrence-Free Survival) +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
OS (Overall Survival) +
Akiba et al. (2018): Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial +
Vitamin D level +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
Nausea +
Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy +
Vomiting +
OS (Overall Survival) +
PFS (Progression-Free Survival) +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Mucositis +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Xerostomia +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Quality of life +
Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial +
Pain +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
Peripheral neuropathy +
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results +
Functionality +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
Peripheral neuropathy +
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation +
Functionality +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
CINV (Chemotherapy-Induced Nausea and Vomiting) +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
CINV (Chemotherapy-Induced Nausea and Vomiting) +
Arslan et al. (2015): Oral Intake of Ginger for Chemotherapy-Induced Nausea and Vomiting Among Women With Breast Cancer +
CINV (Chemotherapy-Induced Nausea and Vomiting) +
Showing 1 related entity.
{ "type": "PROPERTY_CONSTRAINT_SCHEMA", "constraints": { "type_constraint": "_txt", "allowed_values": [ "Anorexia/Cachexia", "Anxiety", "Appetite", "Cerebral oedema", "Cognitive functioning", "Cognitive impairment", "Depression", "Dermatitis", "Distress", "Dysgeusia", "Ejection fraction", "Erectile dysfunction", "Fatigue", "Haematological toxicity", "Hand-foot syndrome", "Ileus (intestinal obstruction)", "Lymphedema", "Menopausal symptoms", "Mood/Affect", "Mucositis", "Nausea", "Nausea and Vomiting", "Neutropenia", "Ototoxicity", "Pain", "Quality of life", "Recurrence rate", "Relaxation", "Stress", "Toxicity", "Vaginal atrophy", "Vomiting", "Weight", "Well-being", "Wound healing", "Xerostomia", "?", "NI", "Esophagitis", "Seroconversion", "Antibodies", "Carnitine level", "Folic acid level", "Haematological indices", "Incidence of acute GVHD (Graft-Versus-Host Disease)", "Length of hospital stay", "Mortality rate", "Non-haematological indices", "Performance Status", "Selenium level", "Tumor response", "Vitamin A level", "Vitamin B6 level", "Vitamin B12 level", "Vitamin B17 level", "Vitamin C level", "Vitamin D level", "Vitamin E level", "Zinc level", "OS (Overall Survival)", "Body composition", "Diarrhoe", "Nutrition status", "PSA level (Prostate-Specific Antigen)", "Taste alteration", "Tumor progression", "DFS (Disease-Free Survival)", "PFS (Progression-Free Survival)", "RFS (Recurrence-Free Survival)", "Carotenoid concentration", "Pharyngitis", "CINV (Chemotherapy-Induced Nausea and Vomiting)", "Fibrosis", "Functionality", "Hand grip strength", "Hormone level", "Musculoskeletal symptoms", "Objective signs and subjective symptoms", "Salivary gland function", "Thromboembolic event rates", "Wound odour", "BMD (Bone Mineral Density)", "PD (Pharmacodynamics)", "Sleep", "Tea polyphenol uptake", "Unspecified effects", "Peripheral neuropathy", "PK (Pharmacokinetics)", "Arterial inflow", "Erythema", "Laboratory parameters", "Mental status/ function", "Neurotoxicity", "Oral ulcus", "Physical functioning", "Additional medication", "Interaction with cancer treatment", "REE (Resting Energy Expenditure)", "Treatment interruption", "Fever", "Infection", "Nerve conduction velocity", "Postoperative morbidity/ complications", "Stomatitis", "Symptom load" ] } }